Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed

MARAVAI LIFESCIENCES HOLDINGS, INC.

EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.
EY's audit reports on financial statements for 2023 and 2024 were unqualified.
EY's internal control report for 2024 contained an adverse opinion citing material weaknesses in revenue/AR and goodwill impairment.
No disagreements on accounting principles or reportable events other than the internal control weakness.
Company did not consult Deloitte before the appointment; EY letter filed as Exhibit 16.1.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.